Corporate Banner
Satellite Banner
Molecular & Clinical Diagnostics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Do you Want to Make the Move from Diagnostics to BiognostiX?

Published: Thursday, February 20, 2014
Last Updated: Thursday, February 20, 2014
Bookmark and Share
Symposium ‘Leading the way from diagnostics to BiognostiX’ to be held on 27 February 2014 in UK.

A symposium focusing on the results of a 3-year EU-funded programme to design a novel fibre-based microfluidic technology to enables rapid and simple point-of-use diagnostic testing will be held at the Hauser Forum, Cambridge, UK, on 27 February 2014.

The BiognostiX™ consortium, headed by experts at FFEI Life Science, has brought together academic, research and commercial partners from five European countries, and now the symposium ‘Leading the way from diagnostics to BiognostiX’, will feature presentations from each, accelerating the process of disseminating the proof of principle data generated as part of the project.

George Hutchinson, Director, FFEI Life Science, said, “We are at a very exciting stage in the development of the programme and we are keen to meet new partners who have a need for the BiognostiX technology. Rapid, low cost, multiplex diagnostic testing on this simple device is an appealing option for a wide range of applications, in veterinary, agri-food and human diagnostic, for example.”

The desired assay biochemistry, microfluidics and a novel particle technology platform are combined on a BiognostiX Chip™. Composed of a fibre-based substrate, each BiognostiX Chip is mechanically treated to create a microfluidic channel pattern.

Reagents are deposited using fluid-jet technologies to deliver picolitre quantities of capture complex - Immuno-Ink™ - into specific zones of the channels.

The simplicity and flexibility of the manufacturing process allows for changes in chip configuration during the assay development process.

The number of microfluidic channels can be varied depending on assay requirements and the residence time of the sample can be adjusted to control the interaction time between the sample and the Immuno-Ink.

The output of the immunoassays can be quantified using densiometric, colorimetric or fluorometric techniques. Once the biochemistry and chip are optimized, they are then fixed for simple, low-cost manufacture.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More than 4,800+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

BiognostiX Symposium Draws a Crowd to Hauser Forum
Company to share the results of this 3-year EU funded FP7 research programme.
Thursday, May 15, 2014
Scientific News
Liquid Biopsies: Miracle Diagnostic or Next New Fad?
Thanks to the development of highly specific gene-amplification and sequencing technologies liquid biopsies access more biomarkers relevant to more cancers than ever before.
Review of the Analysis of Haemoglobin A1c for Diabetes Diagnostics
This paper aims to clarify methods, units, quality requirements, reference and cutoff limits for hemoglobin A1c (HbA1c) and ratio of blood glucose/HbA1c on the basis of the results from Finnish quality control surveys by comparing them to the literature.
Colon Cancer Blocked in Mice
Case Western Reserve University Researchers block common type of colon cancer tumour in mice, laying groundwork for human clinical trial.
Drug - Gene 'One-Two' Punch Against Cancer
Researchers identify gene-drug combinations that, together, target and kill cancer cells while not targeting healthy cells.
Liquid Biopsies Treating Ovarian Cancer
Researchers have discovered a promising monitor and treat recurrence of ovarian cancer. Detecting cancer long before tumours reappear.
72% Rise in Metastatic Prostate Cancer
Over the 2003-2013 period metastatic cancer has increased by an average of 72%, this could be caused by lax screening, more aggressive disease or both.
Lab-Tested Diagnosis Needed When Treating Persistent Diarrhea
New PCR multiplex method makes lab testing more effective.
Biomarker for Multiple Sclerosis Detection Discovered
Winthrop-University Hospital researchers discover biomarker for multiple sclerosis detection.
Scientists Link Bipolar Disorder to Unexpected Brain Region
Researchers from The Scripps Research Institute have found that gene within the brain’s striatum could be linked to biopolar disorder.
Liquid Biopsies: DNA Size Matters
Study finds circulating tumour DNA can be distinguished from healthy DNA through fragment size identification.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!